PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of R. Fortier, et al.

Group Art Unit: 3732 (Anticipated)

Application No.: Continuation of 09/902,636, filed July 12, 2001

Examiner: Eduardo C. Robert (Anticipated)

Filed: Herewith

Docket No.: 10546/57503

For: SYSTEM, METHOD, AND APPARATUS FOR ACCURATELY DEPLOYING

PARTICULAR MEDICAL APPLIANCES AT A TARGET SITE (as amended)

INFORMATION DISCLOSURE STATEMENT

M.S. <u>Patent Application</u>
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). The paragraphs marked below are applicable.

This Information Disclosure Statement is being filed (a) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d), (b) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, (c) before the mailing date of a first Office Action on the merits in the present application, OR (d) before the mailing of a first office action after filing of a request for continued examination. No certification or fee is required.

the me	2. This Information Disclosure Statement is being filed more than three is after the U.S. filing date AND after the mailing date of the first Office Action on erits, but before the mailing date of a final action, Notice of Allowance, or any that otherwise closes prosecution.
	a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
	c. Please debit Deposit Account No. 11-0600 in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p) to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached. 37 CFR §1.97(c)(2).
before Disclo amou	This Information Disclosure Statement is being filed after the mailing date nal action, Notice of Allowance or an action that otherwise closes prosecution, but a payment of the Issue Fee. Applicant(s) hereby request(s) that the Information issure Statement be considered. Please debit Deposit Account No. 11-0600 in the nt of \$180.00 in payment of the petition fee under 37 CFR §1.17(p) to ensure deration of the disclosed information. Two duplicate copies of this paper are need.
	a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	□ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
☐ prese	5. Relevance of the non-English language reference(s) is discussed in the nt specification.

	CARLES BY CARREST	er a service de la companya de la co		
☐ 6. English lar information	nguage version of the fore		counterpart foreign application. An ortion attached for the Examiner's	
7. reference	A concise explanation (s) appears in the Append		e of the non-English language to.	
Noidentification secrecy as patent. The	, filed, which is directe on of this U.S. Patent App s to that application now c	ed to related techolication is not to or upon issuance by requested to c	o co-pending U.S. Patent Application inical subject matter. The be construed as a waiver of of the present application as a onsider the cited application and the pplication.	
identification secrecy as patent. The	Appendix, which are direction of those U.S. Patent A to those applications no	ted to related ted oplications is no w or upon issuar y requested to c	elated applications, identified in the chnical subject matter. The it to be construed as a waiver of ince of the present application as a onsider the cited applications and	
	n No. <u>09/902,636,</u> filed <u>Ju</u>	<u>ly 12, 2001,</u> whic	submitted to the Office in parent ch is relied upon for an earlier filing references are not attached. 37 CFI	
☐ 11. attached h		stracts of the nor	n-English language references are	
1 2.	Other.	• .	•	
			Respectfully submitted,	
			KENYON & KENYON	
Date: <u></u>	Uly 15, 2003		Fred T. Grasso Registration No. 43,644	-

to applicant.